Hyo Sang Lee

Hyo Sang Lee

Auto-generated profile, based on publicly available information

Hyo Sang Lee

Department of Nuclear Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
SCSun Young Chae
Sun Young Chae
SASei Hyun Ahn
Sei Hyun Ahn
SKSung-Bae Kim
Sung-Bae Kim
SHSangwon Han
Sangwon Han
SLSuk Hyun Lee
Suk Hyun Lee
DMDae Hyuk Moon
Dae Hyuk Moon

15 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JYJinyoung Youn
Jinyoung Youn
SLSang-Bin Lee
Sang-Bin Lee
HLHyo Sang Lee
Hyo Sang Lee
HYHyun Ok Yang
Hyun Ok Yang
JPJinse Park
Jinse Park
WJWooyoung Jang
Wooyoung Jang
The roles of autophagy-related proteins as diagnostic or monitoring biomarkers in Parkinson’s disease (PD) have not been clearly elucidated. We recruited 32 patients with early-stage PD and 28 control subjects, and evaluated parkinsonian motor symptoms and dopamine transporter imaging data. Cerebrospinal fluid (CSF) levels of LC3B, Beclin1, and LAMP-2 were estimated using ELISAs, and CSF levels of ATG5, ATG7, and p62 were examined by immunoblotting. Additionally, we also assessed the levels of α-synuclein, total tau, and phosphorylated tau in CSF using ELISAs. Significant differences in the levels of LC3B, LAMP-2, and Beclin1 were observed between the PD and control groups. Using 29.8 pg/mL as the cut-off value for a diagnostic biomarker of PD, CSF LC3B levels exhibited high sensitivity (96.9%) and specificity (89.3%) with an area under the curve of 0.982. Furthermore, LC3B was significantly correlated with the asymmetry index in the caudate and putamen, as estimated by a semi-quantitative analysis of [18F] N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) positron emission tomography (PET). CSF levels of LC3B represented a potential diagnostic and prognostic biomarker of early-stage PD in patients. Based on our findings, molecular biological changes in PD are associated with dysregulation of the lysosomal autophagy pathway.

29 September 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SCSun Young Chae
Sun Young Chae
SKSung-Bae Kim
Sung-Bae Kim
SASei Hyun Ahn
Sei Hyun Ahn
HKHye Ok Kim
Hye Ok Kim
DYDok Hyun Yoon
Dok Hyun Yoon
DMDae Hyuk Moon
Dae Hyuk Moon
The aim of this study was to explore the ability of 18F-fluoroestradiol (18F-FES) PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor (ER)–rich breast cancer. Methods: This was a prospective, single-center study conducted as a substudy of the neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer (NEOCENT) trial. Patients with ER-rich breast cancer were randomized to neoadjuvant chemotherapy (NC) or neoadjuvant endocrine therapy (NET). The baseline SUVmax of 18F-FES PET/CT was measured. The pathologic response was assessed by the Miller–Payne system as nonresponse (grades 1 and 2) and response (grades 3–5). Results: Twenty-six patients were enrolled, with pathologic response achieved in 25 (NC, 12; NET, 13). Two patients achieved pathologic complete response after NC, but the remaining 23 patients had residual disease after NC or NET. Eight of 12 patients responded to NC, and 4 of 13 to NET; the difference was marginally significant (P = 0.07). In the NC group, the 2 patients with 18F-FES–negative tumors and none of the 10 patients with 18F-FES–avid tumors achieved pathologic complete response (P = 0.02). No difference in the SUVmax between responders and nonresponders was observed in either group. However, 5 of 7 NC patients with a baseline SUVmax of less than 7.3 achieved pathologic response, whereas none of the 5 NET patients with an SUVmax of less than 7.3 were responders (P = 0.03). The SUVmax values of the NC group were negatively correlated with percentage reduction of tumor cellularity (r = −0.63, P = 0.03), whereas those of the NET group showed positive correlation (r = 0.62, P = 0.02). During the median follow-up of 74 mo (range, 44–85 mo), recurrence occurred in only 4 NET patients. In patients with an SUVmax of less than 7.3, recurrence occurred in none of the 8 NC patients and 2 of the 5 NET patients (P = 0.13). Conclusion: Postmenopausal women who are ER-positive, but 18F-FES–negative, may benefit from NC rather than NET. 18F-FES PET/CT has the potential to predict response to neoadjuvant therapy in postmenopausal women with ER-rich breast cancer.

11 February 2016 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
HLHyo Sang Lee
Hyo Sang Lee
JOJungsu S. Oh
Jungsu S. Oh
YPYoung Soo Park
Young Soo Park
SJSe Jin Jang
Se Jin Jang
ICIk Soo Choi
Ik Soo Choi
JRJin-Sook Ryu
Jin-Sook Ryu

17 September 2011 in Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
HKHyun Woo Kwon
Hyun Woo Kwon
JPJin Chul Paeng
Jin Chul Paeng
FNFrancis Nahm
Francis Nahm
SKSeog Gyun Kim
Seog Gyun Kim
TZTanzeel Zehra
Tanzeel Zehra
DLDong Soo Lee
Dong Soo Lee

27 March 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
HLHyo Sang Lee
Hyo Sang Lee
BKBeom Seok Ko
Beom Seok Ko
SASei Hyun Ahn
Sei Hyun Ahn
BSByung Ho Son
Byung Ho Son
JLJong Won Lee
Jong Won Lee
DMDae Hyuk Moon
Dae Hyuk Moon